MedPath

HAMAD GENERAL HOSPITAL

🇶🇦Qatar
Ownership
-
Established
1982-01-01
Employees
-
Market Cap
-
Website
https://www.hamad.qa/EN/Hospitals-and-services/Hamad-General-Hospital/Pages/default.aspx

Clinical Trials

3

Active:0
Completed:0

Trial Phases

2 Phases

Phase 4:1
Not Applicable:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Not Applicable
2 (66.7%)
Phase 4
1 (33.3%)

Integrated Life Skill Training and Executive Function Strategies in Children With ASD

Not Applicable
Recruiting
Conditions
Autism Spectrum Disorder
First Posted Date
2023-04-25
Last Posted Date
2023-05-06
Lead Sponsor
Hamad General Hospital
Target Recruit Count
92
Registration Number
NCT05829577
Locations
🇶🇦

Hamad Medical Corporation, Doha, Qatar -doha, Qatar

Efficacy of Extracorporeal Magnetic Stimulation, Pelvic Floor Muscle Exercise, and Combination of Both in Management of Post Radical Prostatectomy Urinary Incontinence

Not Applicable
Recruiting
Conditions
Post Radical Prostatectomy Urinary Incontinence
First Posted Date
2023-01-11
Last Posted Date
2023-01-13
Lead Sponsor
Hamad General Hospital
Target Recruit Count
60
Registration Number
NCT05680168
Locations
🇶🇦

Ambulatory Care Center, Doha, Qatar

To Assess Use of Vancomycin Powder in Craniotomy on Wound Infection Rates

Phase 4
Conditions
Wound Infection
Interventions
First Posted Date
2021-06-08
Last Posted Date
2021-06-08
Lead Sponsor
Hamad General Hospital
Target Recruit Count
500
Registration Number
NCT04917627
Locations
🇶🇦

Hamad General Hospital, Doha, Qatar

News

First-Ever RCT to Evaluate Human Albumin's Effectiveness in Aneurysmal Subarachnoid Hemorrhage Launches in Qatar

• Hamad General Hospital in Qatar initiates groundbreaking randomized controlled trial to assess human albumin's impact on clinical outcomes in aneurysmal subarachnoid hemorrhage patients. • The three-year study will enroll 84 patients to compare albumin-enhanced fluid management versus standard crystalloid therapy, focusing on reducing cerebral vasospasm and improving neurological outcomes. • The trial addresses a critical research gap, as aneurysmal subarachnoid hemorrhage affects working-age populations with up to 60% mortality rate in untreated cases.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.